Identification of CYP3A4 as the predominant isoform responsible for the metabolism of ambroxol in human liver microsomes

References

• ANTILLA S., VAINIO, H., HIETANEN, E., CAMUS, A. M., MALAVEILLE C., BRUN, G., HUSGAFVEL - PURSIAINEN, K., HEllucipc, L., KARJALAINEN, A. and BARTSCH, H., 1992, Immunohistochemical detection of pulmonary cytochrome P4501A and metabolic activities associated with P4501A1 and P4501A2 isozymes in lung cancer patients. Environmental Health Perspectives, 98, 179–182.
   Google Scholar
• BALDWIN, S. J., BLOOMER, J. C., Swill, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BOURRIE M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   Google Scholar
• CLARKE, S. E., AYRTON, A. D. and CHENERY, R. J., 1994, Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica, 24, 517–526.
   PubMed Web of Science ®Google Scholar
• CORNISH -BOWDEN, A., 1995, Fitting the Michaelis—Menten equation by least squares. In A. Cornish-Bowden (ed.), Analysis of Enzyme Kinetic Data (Oxford: Oxford University Press), pp. 27–36. CURTI, P. C., 1972, Steigerung der produktion der oberflichenaktiven substanz der alveolen durch
   Google Scholar
• NA872. Pneumonologic, 147, 62–74.
   Google Scholar
• DAvrEs, B. I., MAESEN, F. P. V. and TEENGS J. P., 1984, Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study. Journal of Antimicrobial Chemotherapy, 14 (suppl. C), 83–89.
   Google Scholar
• GONZALEZ, F. J., 1992, Human cytochrome P450: problems and prospects. Trends in Pharmacological Science, 13, 346–352.
   PubMed Web of Science ®Google Scholar
• GONZALEZ, F. J., CRFSPI, C. L. and GELBorN, H. V., 1991, cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment Mutation Research, 247, 113-127. GONZALEZ, F. J. and GELBOIN, H. V., 1994, Role of human cytochrome P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metabolism Reviews, 26, 165–183.
   Web of Science ®Google Scholar
• GUENGERICH, F. P., 1994, Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicology Letters, 70, 133–138.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., meLLER -ENocH, D. and BLAIR, I. A., 1986, Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology, 30, 2 87–2 95.
   Google Scholar
• GUENGERICH, F. P. and SHIMADA, T., 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391–407.
   PubMed Web of Science ®Google Scholar
• HICKIVIAN, D., WANG, J., WANG, Y. and UNADKAT J. D., 1998, Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metabolism and Disposition, 26, 207–215.
   Google Scholar
• HINOBARA, S. and ABE, M., 1997, Respiratory disease. In S. Hinobara and M. Abe (eds), Today's Therapy 1997 (Tokyo: Igakushoin), pp. 283–317.
   Google Scholar
• HONIG, P. K., WORTHAM, D. C., HuLL, R., ZAMANI, K., Smirm, J. E. and CANTILENA, L. R., 1993, Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharma-codynamics. Journal of Clinical Pharmacology, 33, 12 01–12 06.
   Google Scholar
• HORAI, Y. and IsHizmu, T., 1988, Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism. Rational Drug Therapy, 22, 1–8.
   PubMedGoogle Scholar
• IMAOKA S., ENOMOTO, K., ODA, Y., ASADA, A., FUJIMORI M., SHIMADA, T., FUJITA S., GUENGERICH F. P. and FUNAE, Y., 1990, Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. Journal of Pharmacology and Experimental Therapeutics, 255, 1385–1391.
   Google Scholar
• JAucx, R., BOZLER, G., HAMMER, R. and Koss, F. W., 1978, Ambroxol, studies of metabolism in man and quantitative determination in biological samples. Arzneimittel forschung, 28, 904–911.
   PubMed Web of Science ®Google Scholar
• KisHimoro, W., HIROI, T., SAKAI, K., FUNAE, Y. and IGARAsfil, T., 1997, Metabolism of epinastine, a histamine EL receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Research Communications in Molecular Pathology and Pharmacology, 98, 273–292.
   PubMedGoogle Scholar
• MURRAY, M., 1987, Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents. Drug Metabolism Reviews, 18, 55–81.
   PubMed Web of Science ®Google Scholar
• NAGAOKA, S. and KASE, Y., 1981, Pharmacological study of ambroxol (NA872). Japanese Pharmacology and Therapeutics, 9, 127–136.
   Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• SEKI, T., MATSUMURA, R. and KOHEI, H., 1977, A clinico-pharmacological study on trans-4-(2-amino-3,5 -dibromobenzylamino) cyclohexanol hydrochloride. Japanese Journal of Clinical Pharmacology and Therapeutics, 8, 25–31.
   Google Scholar
• WUNANDS, W. J. A., VAN HERWAARDEN C. L. A. and Vi, T. B., 1984, Enoxacin raises plasma theophylline concentrations. Lancet, ii, 108–109.
   Google Scholar
• ZENG Z., ANDREW, N. W., ARBON, B. H., LUFTER -ATLAS, D. and WANG, R. W., 1998, Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica, 28, 313–321.
   Google Scholar